Rami Manochakian Shares MARIPOSA Study Results Presented at WCLC25
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post by James Chih-Hsin Yang et al. published in NEJM, on X, adding:
”Hot off the press.
Just published NEJM
Overall Survival Results of:
MARIPOSA Study of:
Amivantamab plus Lazertinib vs Osimertinib in 1st line Treatment of EGFR+ Advanced Non-Small Cell LungCancer.
Reminder that we have now two excellent (but different) combination regimens:
Amivantamab + Lazertinib (MARIPOSA)
Osimertinib + Chemotherapy (FLAURA2) with OS data just presented IASLC, WCLC25”
Title: Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
Authors: James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Yu Jung Kim, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Antonio Passaro, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee-Chen Chang, Hiroshige Yoshioka, Michael Thomas, Danny Nguyen, Sai-Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, Manolo D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Ali Nahit Şendur, Ozan Yazici, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Sang-We Kim, Shirish M. Gadgeel, Scott Owen, John Xie, Tao Sun, Jaydeep Mehta, Raja Venkatasubramanian, Mariah Ennis, Elizabeth Fennema, Mahesh Daksh, Amy Roshak, Julie Man, Roland E. Knoblauch, Joshua M. Bauml, Mahadi Baig, Sujay Shah, Seema Sethi, Byoung Chul Cho
Read the Full Article.
More posts featuring Rami Manochakian on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023